Comment
doi: 10.1016/S0140-6736(22)02164-X.
Epub 2022 Nov 6.
Implementation, not hesitation, for SGLT2 inhibition as foundational therapy for chronic kidney disease
Affiliations
- PMID: 36351457
- DOI: 10.1016/S0140-6736(22)02164-X
Item in Clipboard
Comment
Implementation, not hesitation, for SGLT2 inhibition as foundational therapy for chronic kidney disease
Lancet.
.
Free article
No abstract available
Conflict of interest statement
PBM and NS have consulted for and or received lecture fees on SGLT2 inhibition from Napp (PBM), Merck Sharp & Dohme (NS), AstraZeneca (PBM, NS), and Boehringer Ingelheim (PBM, NS) and grant funding paid to the University of Glasgow for SGLT2 inhibition trials from Boehringer Ingelheim (PBM, NS) and AstraZeneca (NS). Unrelated to SGLT2 inhibition but related to chronic kidney disease and cardiometabolic diseases, PBM has consulted for Vifor, Pharmacosmos, GlaxoSmithKline, and Astellas; and NS has consulted for and or received lecture fees from Abbott Laboratories, Afimmune, Amgen, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Janssen, Novartis, Novo Nordisk, Pfizer, and Sanofi, and received grant support paid to the University of Glasgow from Novartis and Roche Diagnostics.
Comment on
-
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.Lancet. 2022 Nov 19;400(10365):1788-1801. doi: 10.1016/S0140-6736(22)02074-8. Epub 2022 Nov 6. Lancet. 2022. PMID: 36351458 Free PMC article.
Similar articles
-
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.Curr Diab Rep. 2022 Jan;22(1):39-52. doi: 10.1007/s11892-021-01442-z. Epub 2022 Feb 3. Curr Diab Rep. 2022. PMID: 35113333 Free PMC article. Review.
-
Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.Ann Pharmacother. 2018 Dec;52(12):1238-1249. doi: 10.1177/1060028018783661. Epub 2018 Jun 17. Ann Pharmacother. 2018. PMID: 29911393
-
Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.Am J Physiol Renal Physiol. 2018 Nov 1;315(5):F1295-F1306. doi: 10.1152/ajprenal.00202.2018. Epub 2018 Jul 18. Am J Physiol Renal Physiol. 2018. PMID: 30019930 Free PMC article.
-
SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond.Lancet Diabetes Endocrinol. 2021 Jan;9(1):3-5. doi: 10.1016/S2213-8587(20)30374-0. Lancet Diabetes Endocrinol. 2021. PMID: 33338414 No abstract available.
-
Inhibition of sodium-glucose cotransporter 2 to slow the progression of chronic kidney disease.Acta Clin Belg. 2022 Aug;77(4):805-814. doi: 10.1080/17843286.2021.1966583. Epub 2021 Aug 17. Acta Clin Belg. 2022. PMID: 34404335 Review.
Cited by
-
Practical Considerations and Implementation of Sodium-Glucose Co-Transporter-2 Inhibitors in Chronic Kidney Disease: Who, When, and How? A Position Statement by Nephrologists.J Prim Care Community Health. 2024 Jan-Dec;15:21501319241259905. doi: 10.1177/21501319241259905. J Prim Care Community Health. 2024. PMID: 39143759 Free PMC article.
-
The temporal trend of disease burden attributable to metabolic risk factors in China, 1990-2019: An analysis of the Global Burden of Disease study.Front Nutr. 2023 Jan 4;9:1035439. doi: 10.3389/fnut.2022.1035439. eCollection 2022. Front Nutr. 2023. PMID: 36687675 Free PMC article.
-
Enhancing therapeutic strategies and drug development for patients with kidney disease.Expert Opin Drug Saf. 2025 Jul 4:1-26. doi: 10.1080/14740338.2025.2525970. Online ahead of print. Expert Opin Drug Saf. 2025. PMID: 40568828 Review.
-
Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis.Endocrinol Metab (Seoul). 2023 Aug;38(4):359-372. doi: 10.3803/EnM.2023.1764. Epub 2023 Jul 24. Endocrinol Metab (Seoul). 2023. PMID: 37482684 Free PMC article. Review.
-
Drug Development in Pediatric Chronic Kidney Disease: A Review of Promising Treatments, Old Challenges, and New Strategies.Paediatr Drugs. 2025 May;27(3):283-291. doi: 10.1007/s40272-025-00684-8. Epub 2025 Feb 10. Paediatr Drugs. 2025. PMID: 39928268 Review.
